Fig. 6: The combination of oHSV30 and CAR-T cells significantly induce tumour regression. | Cell Death & Disease

Fig. 6: The combination of oHSV30 and CAR-T cells significantly induce tumour regression.

From: Arming oncolytic herpes simplex virus with CXCL-11, IL-12 and a single-chain antibody against PD-1 to enhance CAR-T cell therapy in pancreatic ductal adenocarcinoma

Fig. 6: The combination of oHSV30 and CAR-T cells significantly induce tumour regression.The alternative text for this image may have been generated using AI.

A–E Experimental scheme. Panc2-mCD19-HVEM tumour-bearing mice received a single administration of oncolytic viruses or PBS on days 6, 9 and 12, or both three doses of oncolytic viruses (1 × 107 pfu) and CAR-T cells (2 × 106) on the indicated days. B Tumour progression was measured every 3 days during oncolytic virus monotherapy (n = 6 per group). Panc2-mCD19-HVEM tumour-bearing mice were treated intratumourally with oncolytic viruses or PBS on days 6, 9 and 12 and intravenous injection of PBS or CAR-T cells (2 × 106) on day 6 (n = 6 per group). Overall tumour growth profiles (C), survival and tumour-free rate (D) and tumour growth profiles of different groups (E) are illustrated. F–J Experimental scheme. Panc2-mCD19-HVEM tumour-bearing mice received a single administration of oncolytic viruses or PBS on days 6, 9 and 12, or both three doses of oncolytic viruses (1 × 107 pfu) and CAR-T cells (2 × 106) on the indicated days (n = 6 per group). G Tumour progression was measured every 3 days during oncolytic virus monotherapy. For combination therapy, overall tumour growth profiles (H), survival and tumour-free rate (I) and tumour growth profiles of different groups (J) are illustrated. Data represent the mean ± SD. Statistical significance is calculated by one-way ANOVA with Tukey’s significant difference multiple comparisons (B, C, G, H). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Back to article page